Clinical Trials Detalhe

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Visão Geral

Gender

FEMALE

Idade

N/A

Fase

PHASE3

Tipo de Estudo

INTERVENTIONAL

Localização

Pfizer Investigational Site (Coimbra, Portugal)

Pfizer Investigational Site (Evora, Portugal)

Clinicaltrial.gov

https://classic.clinicaltrials.gov/ct2/show/NCT00038467

Sumário

To compare the sequential administration of exemestane with administration of further tamoxifen until 5 years in postmenopausal women with operable breast cancer who have already received 2-3 years of adjuvant tamoxifen, in terms of disease-free survival (DFS), overall survival (OS), incidence of contralateral breast cancer and long-term tolerability.

Condições

Breast Neoplasms

Elegibilidade

Inclusion Criteria: * postmenopausal women with histologically or cytologically confirmed primary breast adenocarcinoma, receiving tamoxifen and have been treated with tamoxifen continuously for between 2 and 3 years and one month, and still free of disease Exclusion Criteria: * unresectable breast cancer * ER negative primary tumor